Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Industry By The Forecast Year 2029?
The eosinophilic granulomatosis with polyangiitis treatment market size has shown strong growth in recent years. It is forecast to increase from $1.28 billion in 2024 to $1.41 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.8%. The historical expansion of this market can be attributed to the rising incidences of Churg Strauss syndrome, an increased demand for effective treatment options, growing research and development activities, an aging population, and enhanced patient awareness.
The market for treating eosinophilic granulomatosis with polyangiitis is projected to experience substantial expansion in the coming years. This market is anticipated to reach a value of $2.04 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth over the forecast period include an elevated emphasis on biologics and targeted treatments, a surge in clinical trial endeavors, growing patient advocacy efforts, a heightened focus on precision medicine and individualized therapies, and the increasing occurrence of asthma within the elderly demographic. Key trends for the forecast duration encompass technological innovations, progress in therapeutic agents and biologics, tailored medicine strategies, partnerships forged between healthcare providers and pharmaceutical firms, and the creation of enhanced diagnostic methodologies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23392&type=smp
What Are The Drivers Pushing New Developments In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
The expanding occurrence of asthma within the older demographic is anticipated to stimulate the advancement of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market moving forward. Asthma is characterized by difficulty in respiration, as the lung’s airways become inflamed and constricted. This condition is becoming more common among the elderly due to a decrease in lung function. When lungs lose their flexibility and airway muscles weaken, breathing becomes more challenging, rendering older individuals more vulnerable to inflammation and respiratory ailments. The increase in asthma cases among the elderly leads to a greater number of individuals being evaluated for associated conditions like eosinophilic granulomatosis with polyangiitis, which frequently manifests initially as asthma, thereby boosting the requirement for its therapeutic interventions. For example, in 2024, the Global Initiative for Asthma, a medical organization based in the US, reported that asthma is a widespread chronic non-communicable disease, affecting over 260 million people worldwide and resulting in more than 450,000 deaths each year. Consequently, the growing incidence of asthma in the aging population is propelling the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market.
Which Key Segments Fueling The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
The eosinophilic granulomatosis with polyangiitis treatmentmarket covered in this report is segmented –
1) By Drug Class: Steroids; Immunosuppressant; Biologics; Immune Globulins
2) By Route Of Administration: Oral; Intravenous; Intramuscular
3) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Drug Stores; Retail Pharmacies
4) By End User: Hospitals; Clinics; Home Healthcare
Subsegments:
1) By Steroids: Glucocorticoids; Mineralocorticoids
2) By Immunosuppressants: Calcineurin Inhibitors; Antimetabolites; Alkylating Agents
3) By Biologics: Interleukin Inhibitors; Monoclonal Antibodies; TNF-alpha Inhibitors
4) By Immune Globulins: Intravenous Immunoglobulin (IVIG); Subcutaneous Immunoglobulin (SCIG)
What Are The Latest Industry Trends Transforming The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
Companies prominent in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market are conducting clinical studies to evaluate the safety and effectiveness of both novel and existing treatments. These clinical trials are designed to broaden treatment possibilities, secure necessary regulatory approvals, and elevate patient care standards. For example, in September 2024, AstraZeneca, a UK-based pharmaceutical and biotechnology firm, disclosed positive outcomes from its MANDARA Phase III trial. The study confirmed that Fasenra (benralizumab) effectively induces remission in patients diagnosed with eosinophilic granulomatosis with polyangiitis. The data revealed that benralizumab achieved remission rates comparable to those of mepolizumab, concurrently reducing the need for oral glucocorticoids. This development signifies an important move towards more precise and steroid-sparing treatment approaches for eosinophilic granulomatosis with polyangiitis.
Which Key Market Players Are Investing In Expansion And Innovation Of Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
Major companies operating in the eosinophilic granulomatosis with polyangiitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Roche Holding AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Intas Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Biogen Inc., Fresenius Kabi, Amgen Inc., Sun Pharmaceutical Industries, Apotex Inc., Cipla Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Alkem Laboratories, NS Pharma.
Download The Full Report For Exclusive Market Findings:
Which Region Currently Holds The Largest Share Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?
North America was the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23392&type=smp
Browse Through More Reports Similar to the Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market 2025, By The Business Research Company
Sewage Treatment Facilities Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/sewage-treatment-facilities-global-market-report
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025
Wastewater Treatment Equipment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model